Abstract: Systems, devices and methods for high-speed I/O margin testing can screen high volumes of pre-production and production parts and identify cases where the electrical characteristics have changed enough to impact operation. The margin tester disclosed is lower cost, easier to use and faster than traditional BERT and scopes and can operate on the full multi-lane I/O links in their standard operating states with full loading and cross-talk. The margin tester assesses the electrical receiver margin of an operation multi-lane high speed I/O link with a device under test simultaneously in either or both directions. In a technology-specific form, an embodiment of the margin tester can be implemented as an add-in card margin tester to test motherboard slots of a mother board under test, or as a as a motherboard with slots to test add-in cards.

Abstract: This disclosure provides methods of treating cancer comprising administering effector cell engaging molecules comprising one or more tumor targeting moieties and one or more effector cell engaging moieties. For example, the effector cell engaging molecules can have a greater cumulative potency for the tumor targeting moieties than the effector cell engaging moieties, the tumor targeting moieties can have greater avidity than the effector cell engaging moieties, and/or can be multimeric. The methods comprise, for example, administering different doses of effector cell engaging molecules based on the subject's symptoms and/or administering chimeric antigen receptor expressing cells.

Abstract: This disclosure provides therapeutic methods for treating cancer including combination therapy with a multimeric anti-DR5 antibody and a cancer therapy, e.g., radiation, an anthracycline, a folic acid analog, a platinum-based agent, a taxane, a topoisomerase II inhibitor, a SMAC mimetic, a vinca alkaloid, a Brutons tyrosine kinase (BTK) inhibitor, a phosphoinositide 3-kinase delta (PI3K?) inhibitor, a myeloid cell leukemia-1 (Mcl-1) inhibitor, or any combination thereof.

Abstract: The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

Abstract: The present invention concerns dosing of anti-EGFL7 antibodies for cancer therapy.